文献速递类风湿关节炎

非侵入性迷走神经刺激治疗类风湿关节炎:一项概念验证研究

Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study.
PubMed 文献 · Lancet Rheumatol · 2021-02-01

这项前瞻性、多中心、开放标签、单臂概念验证研究纳入30例对传统合成DMARDs应答不足且最多使用过一种生物DMARD的活动性类风湿关节炎患者,使用非侵入性耳迷走神经刺激装置每日最多30分钟。

要点

  • ACR20、ACR50、ACR70应答率分别为53%、33%、17%。

核心结论

  • 非侵入性迷走神经刺激装置耐受性良好,患者DAS28-CRP出现有临床意义的下降。
  • 研究为无对照开放标签设计,结果需在此背景下解读,尚需更大规模对照研究确认。

研究设计与样本

  • 前瞻性、多中心、开放标签、单臂概念验证研究,在西班牙6个中心纳入30例18-80岁活动性类风湿关节炎患者。
  • 入组患者对传统合成DMARDs应答不足且最多使用过一种生物DMARD,入组前至少4周停用生物DMARD且研究期间不允许联用。
  • 所有受试者使用非侵入性可穿戴迷走神经刺激装置,每日最多30分钟,脉冲频率20 kHz。
  • 随访访视于基线后第1、2、4、8、12周进行,主要终点为第12周DAS28-CRP较基线的平均变化。

主要发现

  • ACR20应答16例(53%),ACR50应答10例(33%),ACR70应答5例(17%)。
  • 报告4例不良事件,均非严重且未经干预自行缓解。

关键数值与推荐

  • 主要终点为第12周DAS28-CRP较基线的平均变化。

临床怎么用

  • 对于对传统合成DMARDs应答不足且最多使用过一种生物DMARD的活动性类风湿关节炎患者,非侵入性耳迷走神经刺激可能提供一种耐受性良好的辅助治疗选择。
  • 鉴于研究为无对照开放标签设计,临床决策时应结合更大规模对照研究结果综合判断。

局限性

  • 研究为无对照、开放标签设计,结果需在此背景下解读。
  • 样本量较小(纳入30例),随访至第12周。
  • 需更大规模对照研究确认非侵入性迷走神经刺激是否可作为类风湿关节炎的替代治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vagus nerve stimulation delivered with an implanted device has been shown to improve rheumatoid arthritis severity. We aimed to investigate the safety and efficacy of non-invasive stimulation of the auricular branch of the vagus nerve for the treatment of patients with moderately to severely active rheumatoid arthritis. METHODS: This prospective, multicentre, open-label, single-arm proof-of-concept study enrolled patients aged 18-80 years with active rheumatoid arthritis who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and up to one biological DMARD. Biological DMARDs were stopped at least 4 weeks before enrolment and concomitant use was not allowed during the study. All eligible participants were assigned to use a non-invasive, wearable vagus nerve stimulation device for up to 30 min per day, which delivered pulses of 20 kHz. Follow-up visits occurred at week 1, week 2, week 4, week 8, and week 12 after the baseline visit. The primary endpoint was the mean change in Disease Activity Score of 28 joints with C-reactive protein (DAS28-CRP) at week 12 compared with baseline. Secondary endpoints included the mean change in the Health Assessment Questionnaire-Disability Index (HAQ-DI), the proportion of patients with a minimal clinically important difference of 0·22 on HAQ-DI, the proportion achieving American College of Rheumatology (ACR) 20, ACR50, and ACR70 response, and safety analysis. This study is registered with ClinicalTrials.gov (NCT04116866). FINDINGS: Of 35 patients screened for eligibility, 30 (86%) were enrolled at six centres in Spain between Dec 27, 2018, and Oct 24, 2019, of whom 27 (90%) completed the week 12 visit. The mean change in DAS28-CRP at 12 weeks was -1·4 (95%CI -1·9 to -0·9; p<0·0001) from a mean baseline of 5·3 (SD 1·0). 11 (37%) of 30 patients reached DAS28-CRP of 3·2 or less, and seven (23%) patients reached DAS28-CRP of less than 2·6 at week 12. The mean HAQ-DI change was -0·5 (95%CI -0·7 to -0·2; p<0·0001) from a mean baseline of 1·6 (SD 0·7), and 17 (57%) patients reached a minimal clinically important difference of 0·22 or more. ACR20 responses were reached by 16 (53%) patients, ACR50 responses by 10 (33%) patients, and ACR70 by five (17%) patients. Four adverse events were reported, none of which were serious and all of which resolved without intervention. INTERPRETATION: Use of the device was well tolerated, and patients had clinically meaningful reductions in DAS28-CRP. This was an uncontrolled, open-label study, and the results must be interpreted in this context. Further evaluation in larger, controlled studies is needed to confirm whether this non-invasive approach might offer an alternative treatment for rheumatoid arthritis. FUNDING: Nēsos.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Marsal S, Corominas H, de Agustín JJ, et al. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. Lancet Rheumatol. 2021. PMID: 38279410. doi:10.1016/S2665-9913(20)30425-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。